The Minister of Health of the Nation, Ginés González García, said that the Oxford vaccine that will begin to be produced in Argentina will be for the elderly, health workers and those who have some type of previous pathology that makes them vulnerable .
“With that we start as in all vaccinations and then we will see how far it extends, because clearly as with other vaccines, the level of how far we are going to go in immunity is going to be determined by the evolution of the pandemic itself and we believe that with this it is going to have a very strong blow with respect to this evolution, “the minister explained.
González García said they are “happy and proud”, because they are trying to ensure “according to what the Government proposed from the first moment”, access to the vaccine and the moment of access to the vaccine. And he added that also a way to ensure access is that the price is reasonable.
And in that sense he said: “We are also proud because it is not easy to produce the raw material for a vaccine of this complexity and finally that we have the national production capacity fills us with pride.”
The existence of a kind of clause called “emergency use” between laboratories and countries would allow its application while the corresponding permits are being processed, but once phase 3 of development is completed, since it would be applied to healthy people, and that in Argentina it could occur in the month of December, that is, before the end of 2020.
“It isthe vaccine comes to the fore in the world in terms of the moment of the clinical phase in which it is. As of July 20, there are already publications that in the first studies that are being carried out in different countries of the world give an extraordinary immunity capacity that the vaccine has with a single dose. 91 percent of the patients who used the vaccine had immunity, “the minister stressed.
However, González García remarked that “it is neither the only negotiation nor the only alternative. We continue to work with the clinical experience that another provider is carrying out in our country. First to ensure which is the best or the most effective and second in which At the moment we can mount it so that the Argentines are immunized. “
“Before the studies of the experimental phase are finished, it is beginning to be produced. That is what the president said that ‘it is at risk’. If the vaccine were not useful, in reality everything that has been invested in that manufacturing. And the fact that it is done here in Argentina ensures at least a long time, with respect to what was foreseeable from other suppliers, “he said, adding that” the idea that these investigations are led by countries of the The northern hemisphere could potentially put us at risk regarding access. In this way we are taking definitions that ensure access. “
–
